Sorafenib, a type II multi-targeted inhibitor (Raf, VEGFR-1/-2/-3, and PDGFR), is approved for the treatment of RCC and hepatocellular carcinoma (HCC). Here, FLT1 is linked to hepatocellular carcinoma.